Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VTX958 in Moderate to Severe Psoriasis
2022-002887-59Phase 2Terminated
- Sponsor
- Ventyx Biosciences
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing VTX958 with Placebo (2 arms). Primary endpoint: PASI-75 response at Week 16. Started Dec 2022; status: terminated.
02
Drugs
cenacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-002887-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002887-59.